High-dose dual therapy is superior to standard first-line or rescue therapy for helicobacter pylori infection

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 5, 2015, Pages 895-905.e5

  Yang, Jyh Chin ^a   Lin, Chun Jung ^a   Wang, Hong Long ^b   Chen, Jin De ^c   Kao, John Y ^d   Shun, Chia Tung ^a   Lu, Chien Wei ^a   Lin, Bor Ru ^a   Shieh, Ming Jium ^a   Chang, Ming Chu ^a   Chang, Yu Ting ^a   Wei, Shu Chen ^a   Lin, Lin Chih ^e   Yeh, Wen Chun ^f   Kuo, Jen Shin ^a   Tung, Chien Chih ^a   Leong, Yew Loong ^g   Wang, Teh Hong ^a   Wong, Jau Min ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIPEI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e Department of Internal Medicine   (Taiwan)

^f TAIPEI CITY HOSPITAL   (Taiwan)

^g West Garden Hospital   (Taiwan)

Author keywords

Bacterial infection; Microbe; PPI; Proton pump inhibitor; Stomach

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; UREA C 13; ANTIINFECTIVE AGENT;

ABDOMINAL DISEASE; ABDOMINAL DISTRESS; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; CYTOCHROME P450 2C19 GENE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSGEUSIA; FEMALE; GENE; GENOTYPE; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84927911344     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.10.036     Document Type: Article

References (32)

1. McColl K.E.L. Helicobacter pylori infection. NEngl J Med 2010, 362:1597-1604.
2. Malfertheiner P., Megraud F., O'Morain C.A., et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012, 61:646-664.
3. Chey W.D., Wong B.C.Y. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007, 102:1808-1825.
4. Fock K.M., Katelaris P., Sugano K., et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. JGastroenterol Hepatol 2009, 24:1587-1600.
5. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010, 59:1143-1153.
6. Vakil N., Vaira D. Treatment for H.pylori infection: new challenges with antimicrobial resistance. JClin Gastroenterol 2013, 47:383-388.
7. Heep M., Kist M., Strobel S., et al. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000, 19:538-541.
8. Peitz U., Sulliga M., Wolle K., et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002, 16:315-324.
9. Glupczynski Y., Megraud F., Lopez-Brea M., et al. European multicentre survey of invitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001, 20:820-823.
10. Meyer J.M., Silliman N.P., Wang W., et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H.pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002, 136:13-24.
11. Berry V., Jennings K., Woodnutt G. Bactericidal and morphological effects of amoxicillin on Helicobacter pylori. Antimicrob Agents Chemother 1995, 39:1859-1861.
12. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-12.
13. Yang J.C., Lin C.J. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opin Drug Metab Toxicol 2010, 6:29-41.
14. Yang J.C., Yang K.C., Hsu C.T., et al. Amulticenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. JMicrobiol Immunol Infect 1999, 32:1-8.
15. Gisbert J.P., Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006, 23:35-44.
16. Yang J.C., Lu C.W., Lin C.J. Treatment of Helicobacter pylori infection: current status and future concepts. World J Gastroenterol 2014, 20:5283-5293.
17. Greenberg E.R., Anderson G.L., Morgan D.R., et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011, 378:507-514.
18. Hunt R.H. pH and Hp: gastric acid secretion and Helicobacter pylori-implications for ulcer healing and eradication of the organism. Am J Gastroenterol 1993, 88:481-483.
19. Bayerdorffer E., Miehlke S., Mannes G.A., et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995, 108:1412-1417.
20. Agrawal A., Tutuian R., Hila A., et al. Ingestion of acidic foods mimics gastroesophageal reflux during pH monitoring. Dig Dis Sci 2005, 50:1916-1920.
21. Kawakami Y., Akahane T., Yamaguchi M., et al. Invitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000, 44:458-461.
22. Yang J.C., Wang H.L., Chern H.D., et al. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy 2011, 31:227-238.
23. Sugimoto M., Furuta T., Shirai N., et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004, 76:290-301.
24. Furuta T., Shirai N., Takashima M., et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001, 11:341-348.
25. Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013, 62:34-42.
26. Rimbara E., Noguchi N., Kawai T., et al. Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori. JAntimicrob Chemother 2008, 61:995-998.
27. Jafri N.S., Homung C.A., Howden C.W. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naïve to treatment. Ann Intern Med 2008, 148:923-931.
28. Fuccio L., Minardi M.E., Zagari R.M., et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007, 147:553-562.
29. Zagari R.M., Bianchi-Porro G., Fiocca R., et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007, 56:475-479.
30. Megraud F., Lehours P. Helicobacter pylori delection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007, 20:280-322.
31. Liou J.M., Chen C.C., Chen M.J., et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013, 381:205-213.
32. Hsu P.I., Wu D.C., Wu J.Y., et al. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?. Helicobacter 2011, 16:146-152.